Zepbound, Wegovy and Saxenda are all approved by the FDA for the treatment of obesity. Our providers evaluate patients to determine whether or not a patient might be an appropriate candidate for these drug options.
Treatment Considerations include:
- BMI of 27 with a health problem such as high blood pressure, sleep apnea, high cholesterol, etc. or a BMI of 30 or more.
- No personal history of pancreatitis
- No personal or family history of thyroid cancer or MEN2
Some GLP1-analogs are approved for the use of metabolic disease such as Type 2 Diabetes and insulin resistance. These medications include Trulicity, Ozempic, and Mounjaro. Our providers will help to determine whether you meet criteria for coverage during the medical examination and testing or work to maximize your current treatment options.
It is important to understand there is currently no FDA approved generic form of semaglutide.
If a GLP-1 analog is not an option, you may be a candidate for other medications such as Qsymia (phentermine/topiramate), Contrave (naltrexone/buproprion), Adipex, or orlistat.
Your provider may choose to utilize one or more of these medications while working with our team on lifestyle changes.